The role of SIRT1 in diabetic kidney disease

Rabi Yacoub, Kyung Lee and John Cijiang He*

Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

INTRODUCTION

Diabetes mellitus (DM) is a major medical problem worldwide. It is the underlying cause of microvascular disorders such as diabetic nephropathy and retinopathy and macrovascular diseases such as coronary artery and peripheral vascular diseases. Currently, more than 347 million people worldwide are suffering from DM (1), and the World Health Organization projects that it will be the seventh leading cause of death by 2030. The increased prevalence of DM has led to a significant increase in the prevalence of diabetic kidney disease (DKD) with estimates that 44% of all new end stage renal disease (ESRD) cases in US are due to DKD (2, 3). Several factors including hyperglycemia, insulin resistance, renal lipid accumulation, inflammation, and activation of the renin–angiotensin system (RAS) are involved in the pathogenesis of DKD (4) and they activate multiple signaling pathways resulting in kidney cell injury and the development and progression of the disease (5, 6).

Since the discovery of the silent information regulator 2 (Sir2) family and its beneficial effects on aging (7, 8), scientists have shown that the homologs of Sir2 in higher eukaryotic organisms, known as Sirtuins (SIRTs), are a conserved family of a nicotinamide adenine dinucleotide (NAD⁺)-dependent deacetylases/mono-ADP ribosyltransferases that are associated with numerous cellular signaling pathways that include senescence (9–12), apoptosis (13), DNA damage repair (14), and autophagy (12, 15). By far, SIRT1 is the most studied member of this family and its protective roles against kidney injury are well established, making it a promising candidate for targeted therapies to halt disease progression.

GENERAL CELLULAR FUNCTIONS OF SIRT1

SIRT1 exerts its cytoprotective effects through various mechanisms. It has anti-apoptotic, anti-oxidative, and anti-inflammatory effects, along with its regulation of mitochondrial biogenesis and autophagy (Figure 1).

Sirtuins (SIRTs) are members of the silent information regulator 2 family. In mammals, of the seven known SIRTs, SIRT1 function is most studied and has been shown to regulate wide range of cellular functions that affect metabolic homeostasis and aging. SIRT1 exerts anti-apoptotic, anti-oxidative, and anti-inflammatory effects against cellular injury, and protects the cells through the regulation of mitochondrial biogenesis, autophagy, and metabolism in response to the cellular energy and redox status. SIRT1 also promotes vasodilation and protects vascular tissues. In humans and animal models with diabetic kidney disease (DKD), its expression tends to be decreased in renal cells, and increased expression of SIRT1 was found to play a renal protective role in animal models with DKD. In this review, we discuss the role and potential mechanisms by which SIRT1 protects against DKD.

Keywords: SIRT1, diabetic kidney disease, senescence, deacetylation, apoptosis, autophagy, diabetes mellitus, sirtuin

CELLULAR SENESCENCE, OXIDATIVE STRESS, AND MITOCHONDRIAL DYSFUNCTION

Aging is considered the most important contributor to the etiologies of metabolic decline and related diseases (16). This process is thought to be due mainly to the accumulation of oxidative stress related mitochondrial DNA (mtDNA) damages, leading to mitochondrial dysfunction (17). Increasing Sirt1 expression by calorie restriction (CR) in mice abrogated the dysmorphic mitochondrial appearances associated with aging (e.g., mitochondrial swelling and disintegration of cristae), whereas decreasing Sirt1 expression resulted in an early aging phenotype in mice, revealing the important role of SIRT1 on cellular senescence and other aging-related diseases (9–12).

Increased oxidative stress has been associated with aging, and SIRT1 has been shown to combat oxidative stress by modulating transcriptional activities of several key proteins involved in oxidative stress response and mitochondrial biogenesis. Peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) is a transcriptional factor involved in lipid homeostasis and in mitochondrial biogenesis, which prevents and protects against oxidative stress (18). PGC-1α activity appears to be regulated by SIRT1 deacetylation in a tissue specific manner (19). Deacetylation of PGC-1α by SIRT1 has been observed in skeletal muscles, where PGC-1α deacetylation increases mitochondrial biogenesis, mass, and improves exercise endurance (20), and in brown adipose tissue (BAT), and endothelial cells (21).

Recent evidence suggests that SIRT1 can regulate the expression of a longevity gene p66Shc. p66Shc is one of three isoforms encoded by the proto-oncogene SHC (Src homologous and collagen) and has been shown to promote oxidative stress, leading to mitochondrial dysfunction, senescence, and apoptosis (22, 23). Deletion of p66Shc in Akita diabetic mice showed a renoprotective phenotype that included the attenuation of oxidative stress and glomerular/tubular injury and reduction in albuminuria (24, 25).
Several studies have shown that SIRT1 negatively regulates expression of p66^{Shc} through deacetylation of histone H3 on its promoter (26). Treating different cell lines that do not usually express p66^{Shc} with histone deacetylase inhibitors induced p66^{Shc} expression (23, 26), and deletion of p66^{Shc} in Akita diabetic mice resulted in upregulation in SIRT1 expression in mice kidneys and ameliorated kidney fibrosis and preserved podocytes mass and function (24).

**AUTOPHAGY AND APOPTOSIS**

Autophagy and apoptosis are two closely related processes that are triggered by common upstream signaling pathways to constitute a stress adaptation, where in general autophagy inhibits apoptosis to maintain survival (27, 28). SIRT1 exerts an anti-apoptotic and pro-autophagic responses in cells under stress conditions by directly deacetylating essential autophagy proteins (Atg), such as Atg5, Atg7, and Atg8 (29), and by deacetylation of transcription factors, such as FOXO3a, to increase the expression of autophagy proteins (12, 15). Deacetylation of FOXO3a by SIRT1 also prevents apoptosis by enhancing the expression of p27^{Kip1}, a cyclin-dependent kinase inhibitor that causes G1 arrest to maintain cell viability (12, 30).

In addition, SIRT1 has been shown to deacetylate and inactivate the transcriptional activity of p53, a tumor suppressor responsible of maintaining cellular integrity by inducing cell-cycle arrest, and if necessary evoking apoptotic cell death (31). With aging, the depletion of NAD^{+} storage attenuates SIRT1 activity, leading to hyperacetylation of p53. p53 has been shown to stimulate or repress autophagy depending on its subcellular localization, where cytoplasmic p53 promotes apoptosis and inhibits autophagy (32). While it is known that SIRT1 regulates p53 function by deacetylation, whether it affects its cytoplasmic localization is not known (33).

**ADIPOSE TISSUE TRANSFORMATION**

One of the mechanism by which CR is thought to extend life span is through fat mobilization. Upon CR, SIRT1 binds and represses the fat regulator peroxisome proliferator-activated receptor-gamma (PPARγ), attenuating adipogenesis, and triggering lipolysis (34). It also selectively decreases white adipose genes Angiotsinsinogen (Agt), Resistin, Wahn1L, Chemerin, and Pank3 (35). PPARγ deacetylation by SIRT1 causes also a lipid transformation from white adipose tissue (WAT) to BAT through regulating ligand-dependent coactivator/corepressor exchange at the PPARγ transcriptional complex (35). WAT distribution affects metabolic risk and is linked to metabolic diseases as obesity, diabetes, and dyslipidemia (36). The metabolic benefits of this conversion include prevention of diet-induced obesity and increased insulin sensitivity (37).

**ROLE OF SIRT1 IN DM**

It is well established that the risk of micro and macrovascular complications in patients with DM is closely related to the glycemic control. In the fasting state, hyperglycemia is directly related to hepatic glucose production, which in turn, along with the decreased insulin production or increased insulin resistance, is responsible for the hyperglycemia in the postprandial state (38). SIRT1 participates in regulating glucose homeostasis through regulating hepatic glucose production, lipid metabolism and insulin production, and sensitivity (39–42).

**HYPERGlyCWell established that the risk of micro and macrovascular complications in patients with DM is closely related to the glycemic control. In the fasting state, hyperglycemia is directly related to hepatic glucose production, which in turn, along with the decreased insulin production or increased insulin resistance, is responsible for the hyperglycemia in the postprandial state (38). SIRT1 participates in regulating glucose homeostasis through regulating hepatic glucose production, lipid metabolism and insulin production, and sensitivity (39–42).

**HYPERGLYCEMIA**

SIRT1 decreases hepatic glucose production via deacetylation and activation of the AMPK kinase LKB1 (39). When activated, AMPK switches off hepatic glucose, cholesterol, and triglyceride productions and promotes fatty acid oxidation. AMPK in turn also activates SIRT1 via increasing its substrate NAD^{+} (43). This reciprocal activation/dynamic interaction between AMPK and SIRT1 is disrupted by hyperglycemia, which decreases AMPK expression, leading to reduced SIRT1 expression (44).

**LIPID METABOLISM AND INSULIN PRODUCTION AND SENSITIVITY**

Under the fasting state, hepatic SIRT1 regulates lipid homeostasis and gluconeogenesis by positively regulating PPARα and its coactivator PGC-1α (10). In addition, SIRT1 also suppresses glycolysis via deacetylation of phosphoglycerate mutase-1 (PGAM1) and decreasing the expression of glycolysis genes glucose-6-phosphatase (G6pase) and liver pyruvate kinase (LPK) (10, 40). In contrast, under the feeding state hepatic SIRT1 negatively regulates gluconeogenesis via mTors2/Akt signaling pathway, resulting in decreased transcription of gluconeogenic genes glucose-6-phosphatase (G6pase) and phosphoenolpyruvate carboxykinase (Peck) (45). Experimental mice model of hepatic SIRT1 deficiency displayed hyperglycemia, glucose intolerance, hepatic insulin resistance, and oxidative stress in insulin-sensitive organs through disrupted mTors2/Akt signaling (45). This bimodal regulation of gluconeogenesis under feeding/fasting states by SIRT1 promotes adaptation to nutrient deprivation (10, 41).

SIRT1 also enhances insulin secretion from the pancreatic beta cells by regulating the expression of uncoupling protein 2 (Ucp2) (42), and decreases insulin resistance via reducing the expression of the proteins in the insulin receptor signaling pathway,
such as protein tyrosine phosphatase 1B (PTP1B), and by inhibiting insulin-induced IRS-2 (insulin receptor substrate-2) tyrosine phosphorylation by deacetylation (46, 47).

**EXPRESSION OF SIRT1 IN DIABETIC KIDNEY**

SIRT1 expression changes under different physiological and morbid conditions. It is decreased in conditions of chronic metabolic stress, oxidative stress, or hypoxia that drives the pathophysiology of age-related diseases including diabetes, cardiovascular, and renal diseases. In aging kidneys both the expression and activity of SIRT1 is decreased due to age-associated reduction in systemic NAD^+ biosynthesis (12). Similarly, reduction in SIRT1 was observed in kidney glomeruli and tubulointerstitial compartments of patients with mild to severe DKD, which was inversely correlated with the histopathological severity of the renal disease and with the amount of proteinuria (48, 49). Experimental mouse models of DM similarly showed a loss of Sirt1 in renal proximal tubules (PT) and podocytes (48, 49), where the loss of PT Sirt1 preceded the loss of podocyte Sirt1 and the concomitant albuminuria. Interestingly, restoration of PT Sirt1 was sufficient to increase pore densities in podocytes and to mitigate albuminuria and worsening of DKD (49), suggesting that PT Sirt1 confers protection in maintaining the glomerular structure and function during the early stages of DKD and that therapeutic agents that increase the renal SIRT1 expression and activity may have a favorable impact in slowing the disease progression of DKD.

**ROLE AND CELLULAR MECHANISMS OF SIRT1 IN DKD**

Among many studies indicating SIRT1’s protective role in numerous different cell types, several studies have described its protective role in different kidney cells. Some of these effects are in the general context of SIRT1’s cytoprotective actions, while others seem to have a unique specificity to specialized renal cells. In the following section, we will discuss the deleterious effects of reduced SIRT1 expression on kidney cells, and the mechanisms by which SIRT1 is found to exert its benefits on renal cells and on the concomitant inflammation, angiogenesis, and fibrosis, all of which contributes to the progression of DKD (Table 1).

**PODOCYTES**

One of the earliest changes in DKD is the loss of podocytes, leading to proteinuria and further kidney damage (60–62). In DKD, podocyte apoptosis is aggravated by hyperglycemia via increasing the production of advanced glycation end products (AGEs), which in turn increases FOXO4 acetylation and suppresses SIRT1 expression (48). This decreased SIRT1 expression leads to the accumulation of acetylated FOXO4 and to the expression of the pro-apoptotic gene Bcl2l11 (also known as Bim), resulting in apoptosis (48). Hyperglycemia also stimulates the generation of intracellular reactive oxygen species (ROS) through NADPH oxidase and mitochondrial pathways, leading to activation of the pro-apoptotic p38 mitogen-activated protein kinase (p38 MAPK) and Caspase 3 in podocytes (5).

**PROXIMAL TUBULAR CELLS**

Tubular SIRT1 has been shown to affect podocyte function via maintaining a high glomerular nicotinamide mononucleotide (NMN) concentration via diffusion of the NMN produced in the PTs (49, 63). Decreased expression of NMN has been observed in DKD (64), which is likely to be the first pathological changes preceding proteinuria (65). PT SIRT1 communicates with podocytes through the release of NMN. PT SIRT1 appears to negatively modulate the expression of the tight junction protein Claudin-1 (49). In healthy conditions, Claudin-1 is not expressed in podocytes but primarily expressed on glomerular parietal cells. However, in diabetic mice models podocytes express Claudin-1, possibly as a part of a podocyte dedifferentiation mechanism that occurs in DKD or by reorganization of the podocyte actin cytoskeleton (63). SIRT1 also protects PTs under hypoxic conditions by inducing autophagy and inhibiting apoptosis (12, 24).

**RENAL MEDULLA**

In a healthy individual, a quarter of the cardiac output is directed to the kidneys, with most of this flow going to the cortex to optimize glomerular filtration. However, the renal medulla’s blood flow is low to preserve osmotic gradient and enhance concentration ability. The renal medulla is also under chronic and constant oxidative stress due to the rapid change in interstitial tonicity and the low oxygen tension (66, 67). A small percentage of oxygen consumed by the mitochondria is incompletely reduced to ROS, which then targets the other mitochondrial components and augments the generation of increased ROS by the injured mitochondria. Under these conditions, renal mitochondria undergo a constant autophagy process. To cope with hypoxia, higher organisms’ adaptive mechanisms includes switching energy metabolism from oxygen phosphorylation to HIF-1 mediated anaerobic glycolysis (68), which concurrently blocks mitochondrial energy metabolism and biogenesis (69). SIRT1 is normally expressed in the inner medulla and is upregulated during intermittent hypoxia-reoxygenation and protects against oxidative stress via stabilizing HIF-1α and regulating of cyclooxygenase 2 (COX2) (54, 70). However in chronic hypoxic state, the renal medulla endures in DKD, SIRT1 activity is inhibited due to decreased NAD^+ (58).

**MESANGIAL CELLS**

Mesangial injury and expansion mark early histological changes in DKD, and they are correlated closely with the degree of albuminuria. SIRT1 attenuates TGF-β1 induced mesangial cell apoptosis through its direct interaction and deacetylation of Smad7, enhancing its ubiquitin-mediated proteasome degradation (51). SIRT1 also prevents high glucose-induced mesangial cells hypertrophy by augmenting the AMPK–mTOR signaling pathway (53) and subsequently blocking the activation of Akt signaling (71). NAD^+ treatment mitigates the high glucose-induced Akt and mTOR phosphorylation in cultured mesangial cells (53).

**ENDOTHELIAL CELLS AND ANGIOGENESIS**

As in diabetic retinopathy, new vessel formation is observed in DKD patients (72) and in animal models (73), contributing to its pathogenesis. Early on in DKD, there is an increase in endothelial cells number, caused by the imbalance between proliferation and apoptosis, where VEGF-A appears to be the major
| Renal cell/compartment | SIRT1 role                        | Mechanism                                                                 | Reference |
|------------------------|----------------------------------|---------------------------------------------------------------------------|-----------|
| Podocytes              | Anti-apoptosis                    | Deacetylates FOXO4, decreasing the expression of the pro-apoptotic gene   | (48)      |
|                        |                                  | Bcl211 (Bim)                                                              |           |
|                        |                                  | Negatively regulating Claudin-1                                            | (49)      |
| Proximal tubular cells| Decreases apoptosis and improves| Deacetylates FOXO3a leading to enhanced expression of Bnip3 (pro-autophagy) and p27Kip1 (anti-apoptosis) | (12)      |
|                        | autophagy                         | Decreases age-associated mtDNA oxidative damages                         | (12)      |
|                        | Attenuates hypoxia-associated     |                                                                       |           |
|                        | mitochondrial damage              | Maintains the glomerular structure through suppressing Claudin-1 expression | (49)      |
|                        |                                  | in podocytes                                                             |           |
|                        | Decreases albuminuria             | Prevents TGF-β1 induced fibrotic response via Smad3 deacetylation         | (60)      |
| Mesangial cells        | Anti-apoptosis                    | Attenuates TGF-β1 induced mesangial cell apoptosis through its direct     | (51)      |
|                        |                                  | interaction and deacetylation of Smad7                                   |           |
|                        | Inhibition of ROS-mediated        | P63 deacetylation                                                         | (52)      |
|                        | apoptosis                         |                                                                           |           |
|                        |                                  | Prevents hyperglycemia-induced hypertrophy by augmenting the AMPK-mTOR    | (53)      |
|                        |                                  | signaling pathway                                                        |           |
|                        |                                  | Decreases mesangial expansion                                             | (53)      |
|                        |                                  |                                                                           |           |
| Renal medulla          | Protects against oxidative injury | Stabilizes HIF-1α and regulates COX2 during intermittent hypoxia-reoxygenation | (64)      |
|                        | Reduces apoptosis and fibrosis    | Regulates COX2 decreasing oxidative stress-induced apoptosis              | (64)      |
| Collecting ducts       | Solute and water handling         | Represses α-ENaC transcription                                             | (55)      |
| Endothelial cells      | Prevents early senescence and     | Uregulates MMP-14 leading to increased matrilysic activity and angiogenesis| (58)      |
|                        | fibrosis                          | Prevents increased permeability and cellular junction disruption via       | (57)      |
|                        |                                  | downregulation of VEGF and Flik-1 (in podocytes too)                      |           |
|                        | Modulates angiogenesis            |                                                                           |           |
|                        | Promotes vasodilatation           | Decreases the expression of AT1R, and increases NO by deacetylating eNOS  | (58)      |
| Glomeruli              | Attenuates hypoxia-associated     | Decreases age-associated mtDNA oxidative damages                         | (12)      |
|                        | mitochondrial damage              |                                                                           |           |
| Renal cortex           | Anti-inflammatory                 | Decreases macrophages infiltrates, deacetylates NF-κB p65 subunit and     | (59)      |
|                        |                                  | negatively regulates MCP-1, ICAM-1, and VCAM-1                           |           |
| Glomerular/tubular     | Decreases cellular senescence     | Deacetylates H3 on p66Shc promoter                                        | (24)      |
|                        | compartments                      |                                                                           |           |
|                        | apoptosis                          |                                                                           |           |

FOXO, forkhead box protein O; Bnip3, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3; ACE2, angiotensin-converting enzyme 2; Ang1–2 and Ang2, angiotensin-(1–7); COX2, cyclooxygenase 2; HIF-1α, hypoxia-inducible factor 1α; α-ENaC, α-epithelial sodium channel; MMP-14, matrix metalloproteinase-14; VEGF, vascular endothelial growth factor; Flik-1, fetal liver kinase-1; AT1R, angiotensin II receptor-type 1; NO, nitric oxide; eNOS, endothelial nitric oxide synthase; NF-κB, nuclear factor kappa B; MCP-1, monocyte chemotactic protein-1; ICAM-1, intercellular adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1.

driver of this imbalance. Other factors affecting angiogenesis include nitric oxide deficiency, glomerular hypertension (74), altered expressions of VEGF receptors 1 and 2, Angiopoietin 2, and Tie-2 (57, 75, 76). In vivo and in vitro studies have shown that resveratrol (RSV), a SIRT1 activator, downregulates high glucose-induced VEGF-A and Flik-1 (VEGFR-2) expressions in both glomerular podocytes and endothelial cells. RSV also inhibits VEGF-A induced increased permeability and cellular junction disruption of cultured endothelial cells (57). SIRT1 also maintains endothelial cells function and prevents early senescence via upregulating matrix metalloproteinase-14 (MMP-14), an important factor for endothelial cells regeneration after injury. MMP-14 cleavage products serve as a ligand for epidermal growth factor (EGF) receptors (56). Endothelial cells have also been shown to express early senescence features in presence of high glucose through the down regulation of SIRT1 expression, leading to an increased acetylation of FOXO1 by p300 (77).

**INFLAMMATION**

Microinflammation of the glomeruli and tubulointerstitial regions and subsequent extracellular matrix expansion are common...
pathways for the progression of DKD, which occurs in response to renal damage as a defense mechanism. This dynamic process of pro-inflammatory macrophages M1 and anti-inflammatory macrophages M2 recruitment to the kidneys eventually leads to kidney fibrosis, highlighting the importance of inflammation as a therapy target to slow the DKD progression (78). SIRT1 can deacetylate NF-κB p65 subunit and negatively regulate the NF-κB signaling mediated expression of the inflammation-related proteins monocyte chemotactic protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion protein-1 (VCAM-1) (59). Dietary restriction in Wistar fatty rats restores Sirt1 expression and ameliorates diabetic nephropathy abnormalities (i.e., albuminuria, mesangial matrix expansion, and renal fibrosis), which is in part mediated by Sirt1’s anti-inflammatory effects as evidenced by decreased macrophages infiltrates and changes in expression of NF-κB p65, MCP-1, ICAM-1, and VCAM-1 (59).

FIBROSIS

Kidney fibrosis is the final outcome of progressive DKD, and it results in a significant destruction of normal kidney structure accompanied by functional deterioration. TGF-β1 is upregulated in response to various kidney injury stimuli, causing renal fibrosis and epithelial–mesenchymal transformation of the renal tubules (79). Recent studies have identified Smad2 and Smad3 acetylation in response to TGF-β1 stimulation (50, 80, 81) and shown that the RSV treatment of cultured PTs leads to deacetylation of Smad3 (50). In addition, RSV administration abolished TGF-β1/Smad3 induced up-regulation of α-SMA, collagen IV, and fibronectin in UUO mouse model of kidney fibrosis, suggesting that SIRT1 activity may be essential in preventing TGF-β1 induced fibrotic response via Smad3 deacetylation (50).

RENNIN–ANGIOTENSIN SYSTEM AND SIRT1

Rennin–angiotensin system, especially Angiotensin II (AngII) is closely associated with the development and progression of DKD. RAS inhibition by angiotensin-converting enzyme inhibitors (ACEi), which inhibits the conversion of AngI to AngII, or angiotensin receptors blockers (ARBs) decreases proteinuria in patients with diabetic nephropathy and halts the disease progression to ESRD, thus improving patient survival (82). Angiotensin-converting enzyme 2 (ACE2), a homolog of ACE not inhibited by ACEi, counteracts AngII effects by hydrolyzing AngII into Angiotensin 1–7 (Ang 1–7), which in turn protects against DKD by increasing tissue triglyceride degradation and decreasing kidney weight, mesangial expansion, proteinuria, and renal fibrosis (4). SIRT1 regulates RAS by binding and activating ACE2 promoter, leading to increased Ang 1–7 concentrations (4, 44). It also promotes vasodilatation by decreasing the expression of the potent vasoconstrictor angiotensin II receptor-type 1 (AT1R), and protects vascular tissues through increased nitric oxide production by deacetylating eNOS in endothelial cells (58).

WATER HANDLING

Diabetes mellitus is associated with a significant polyuria and natriuresis, as well as increased plasma aldosterone and anti-diuretic hormone arginine vasopressin (AVP) levels. Studies have identified serum and glucocorticoid induced kinase-1 (SGK-1) as a key signaling element in diabetic nephropathy (83, 84). Under the hyperglycemic state the increase in Ca2+ and TGF-β1 leads to upregulation of SGK-1 in kidney, which regulates epithelial Na+ channel (ENaC) activation, leading to increased sodium absorption (85). A physiological role for SIRT1 in regulating the α-ENaC expression has been reported in cultured renal inner medullary collecting duct cells (mIMCD3) (55). SIRT1 interacts with Dot (disruptor of telomeric silencing)-1, a histone H3K79 methyltransferase, and enhances its activities on histone H3K79 methylation in chromatin along the α-ENaC promoter, and thereby repressing α-ENaC transcription in mIMCD3 cells (55).

CONCLUSION AND PROSPECTS

Since the first description of the Sir2 family and its effects on longevity in yeast, our understanding of the specific actions and role of SIRT1 on different kidney diseases have increased tremendously. Administration of SIRT1 activators showed a restoration of SIRT1 levels, decreased albuminuria, glomerular hypertrophy, and kidney fibrosis in DKD models (86–90). The mechanisms by which these activators exert their beneficiary effects are currently under extensive research, highlighting the importance of developing therapies to increase either SIRT1 expression or activity in patients with DKD to prevent disease progression. In addition, single nucleotide polymorphisms (SNPs) within the gene encoding SIRT1 have shown to have a directionally consistent association with diabetic nephropathy leading to the assumption that SIRT1 not only play a protective role, but certain SNPs variations of SIRT1 might predispose an individual to DKD (91). These findings warrant further investigations into the functions of these SNPs variations, and to develop new strategies for protection against renal diseases.

REFERENCES

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet (2011) 378(9785):31–40. doi:10.1016/S0140-6736(11)60679-X
2. Mauer M, Zimmel B, Gardiner R, Suissa S, Sainio K, Strand T, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 361(1):40–51. doi:10.1056/NEJMoa0804040
3. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol (2007) 18(10):2644–8. doi:10.1681/ASN.2007020220
4. Mori J, Patel VB, Ramprastha T, Alrob OA, DesAuilniers J, Scholey JW, et al. Angiotensin I-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol (2014) 306(8):F812–21. doi:10.1152/ajprenal.00655.2013
5. Suozzato K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes (2006) 55(1):225–33. doi:10.23736/sj.diabetes.55.01.06.db05–0894
6. Chand PW, Yu Q, Fang W, Uribarri J, He JC. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int (2007) 72(8):965–76. doi:10.1038/sj.ki.5002436
7. Sinclair DA, Guarente L. Extrachromosomal rDNA circles – a cause of aging in yeast. Cell (1997) 91(7):1033–42. doi:10.1016/S0092-8674(00)80493-6
8. Kaebelerlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genet Dev (1999) 13(19):2570–80. doi:10.1101/gad.13.19.2570

9. Cohen HY, Miller C, Bitterman KJ, Walf NR, Hekking B, Kessler B, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science (2004) 305(5682):390–2. doi:10.1126/science.1099196

10. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature (2005) 434(7029):113–8. doi:10.1038/nature03354

11. Bourdon L, Cohen D, Robinson A, Motta MC, van Een E, Coopik A, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell (2007) 6(4):579–67. doi:10.1111/j.1440-1721.2007.00335.x

12. Kume S, Utsu T, Horieki K, Chini-Kanasaki M, Isshiki K, Araki S, et al. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest (2010) 120(4):1043–55. doi:10.1172/JCI41376

13. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frys AE, Pandita TK, et al. SIR2/SIRT1 functions as an NAD-dependent p35 deacetylase. Cell (2001) 107(2):149–59. doi:10.1016/S0008-8741(01)00527-X

14. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev (2000) 14(9):1011–26. doi:10.1101/gad.14.9.1021

15. Nath KA. The role of Sirt1 in renal rejuvenation and resistance to stress. J Clin Invest (2010) 120(4):1026–8. doi:10.1172/JCI42184

16. Barzilai N, Huffman DM, Muzumdar RH, Bartke A. The critical role of metabolic pathways in aging. Diabetes (2012) 61(6):1315–22. doi:10.2337/db11-0810

17. Hena A, Sanz A, Kujovst GC, Pamplona R, See AO, Hoyer T, et al. Mitochondrial DNA mutations induce mitochondrial dysfunction, apoptosis and sarcopenia in skeletal muscle of mitochondrial DNA mutant mice. PLoS One (2010) 5(7):e11468. doi:10.1371/journal.pone.0011468

18. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M. PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res (2005) 66(3):562–73. doi:10.1016/j.cardiores.2005.01.026

19. Xu Q, Xia P, Li X, Wang W, Liu Z, Gao X. Tetratetramethylpyrazine ameliorates high glucose-induced endothelial dysfunction by increasing mitochondrial biogenesis. PLoS One (2014) 9(2):e88243. doi:10.1371/journal.pone.0088243

20. Higashida K, Kim SH, Jung SR, Asaka M, Holloszy JO, Han DH. Effects of caloric restriction on mitochondrial function. J Biol Chem (2009) 284(47):32440–9. doi:10.1074/jbc.M906644200

21. Lagouge M, Argmann C, Gerhart-Hines Z, Feige JN, Milne JC, et al. Altered NAD+ metabolism in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 35(6):1364–79. doi:10.2337/db11-0413

22. Menini S, Amadio L, Oddi G, Ricci C, Pesce C, Pugliese F, et al. Deletion of p66Shc longevity gene protects against experimental diabetic glomerulopathy by preventing diabetes-induced oxidative stress. J Biol Chem (2013) 288(47):35435–46. doi:10.1074/jbc.M113520200

23. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab (2009) 9(4):327–38. doi:10.1016/j.cmet.2009.02.006

24. Price NL, Gomes AP, Ling AL, Duarte FY, Martin-Montalvo A, North BJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab (2012) 15(5):675–90. doi:10.1016/j.cmet.2012.04.003

25. Hallows WC, Yu W, Dem JM. Regulation of glycolytic enzyme phosphoglycerate mutase-1 by Sirt1 protein-mediated deacetylation. J Biol Chem (2012) 287(6):5850–8. doi:10.1074/jbc.M111317404

26. Inzucchi SE, Berges RM, Busc IAM, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 35(6):1364–79. doi:10.2337/db11-0413

27. Clarke NE, Belyaev ND, Lambert DW, Turner AJ. Epigenetic regulation of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. J Biol Chem (2007) 282(21):153–64. doi:10.1074/jbc.M605107200

28. Seale P, Conroe HM, Estall J, Kajimura S, Frontini A, Ishibashi I, et al. Pmrd16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest (2011) 121(1):96–105. doi:10.1172/JCI44271

29. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Norgaard L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature (2009) 458(7241):1056–60. doi:10.1038/nature07813

30. Clarke NE, Belyaev ND, Lambert DW, Turner AJ. Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress. Circ Res (2014) 116(7):507–16. doi:10.1161/CIRCRESAHA.114.302929

31. Wang RH, Kim HS, Xiao C, Xu X, Gavrileova O, Deng CX. Hepatic Sirt1 deficiency in mice impairs mtTors/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest (2011) 121(11):4477–90. doi:10.1172/JCI46243

32. Sun C, Zhang F, Ge X, Yan T, Chen X, Shi X, et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab (2007) 6(4):307–19. doi:10.1016/j.cmet.2007.08.014

33. Zhang J. The direct involvement of SIRT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J Biol Chem (2007) 282(47):34356–64. doi:10.1074/jbc.M706444200

34. Huang PY, Dai Y, Liu R, He H, Kretzler M, Jim B, et al. Alteration of forkhead box O (foxo) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One (2011) 6(8):e23566. doi:10.1371/journal.pone.0023566

35. Hasegawa K, Wakisano S, Simic P, Sakamaki Y, Minakuchi H, Fujimura K, et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med (2013) 19(11):1496–504. doi:10.1038/nm.3363
50. Li J, Qu X, Ricardo SD, Bertram JF, Nikolic-Paterson DJ. Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deglaciation of SIRT3. *J Am Chem Soc* (2010) 132(3):1065–71. doi:10.1021/ja902100j.

51. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Ishiki K, et al. SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deglaciation. *J Biol Chem* (2007) 282(1):151–8. doi:10.1074/jbc.M609504200.

52. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isom M, et al. Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deglaciation. *Free Radic Biol Med* (2006) 40(12):2175–82. doi:10.1016/j.freeradbiomed.2006.02.014.

53. Zhao L, Fu B, Bai X, Zhang B, Wu L, Cui J, et al. NAD blocks high glucose induced mesangial mesangial hypertrophy via activation of the sir2p-AK-mTOR pathway. *Cell Physiol Biochem* (2011) 27(6):681–90. doi:10.1155/2011/300377.

54. He W, Wang Y, Zhang MZ, You L, Davis LS, Fan H, et al. Sirt1 activation protects the mouse renal medulla from oxidative injury. *J Clin Invest* (2010) 120(4):1056–68. doi:10.1172/JCI41563.

55. Zhang D, Li S, Cruz P, Kone BC. Sirtuin 1 functionally and physically interacts with disruptor of telomeric silencing-1 to regulate alpha-ENaC transcription in collecting duct. *J Biol Chem* (2009) 284(21):20977–26. doi:10.1074/jbc.M109.020073.

56. Vasko R, Xavier S, Chen J, Lin CH, Ratliff B, Rabadi M, et al. Endothelial sirtuin 1 deficiency perpetuates nephrosclerosis through downregulation of matrix metalloproteinase-14: relevance to fibrosis of vascular senescence. *J Am Soc Nephrol* (2014) 25(2):276–91. doi:10.1681/ASN.2013010069.

57. Wen D, Huang X, Zhang M, Zhang L, Chen J, Yu Q, et al. Resveratrol attenuates diabetic nephropathy via modulating angiotensin. *Plos One* (2013) 8(12):e82336. doi:10.1371/journal.pone.0082336.

58. Miyazaki R, Ichiki T, Hashimoto T, Inanaga K, Imayama I, Sadoshima J, et al. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* (2008) 28(7):1263–9. doi:10.1161/ATVBAHA.108.166991.

59. Kitada M, Takeda A, Nagai T, Ito H, Kanasaki K, Koya D. Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty rats (fa/fa): rats of a model of type 2 diabetes. *Exp Diabetes Res* (2011) 2011:908185. doi:10.1155/2011/908185.

60. Matusaoka T, Sandgren E, Shintani A, You L, Davis LS, Fan H, et al. Podocyte injury damages other podocytes. *J Am Soc Nephrol* (2011) 22(7):1275–83. doi:10.1681/ASN.2010090923.

61. Mundel P, Shankland SJ. Podocyte biology and response to injury. *J Am Soc Nephrol* (2002) 13(12):2005–15. doi:10.1097/01.ASN.0000039661.06947.FD.

62. Eid AA, Gorin Y, Fagg BM, Maalouf R, Barnes JL, Block K, et al. Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. *Diabetes* (2009) 58(5):1201–11. doi:10.2337/db08-1536.

63. Nihalani D, Susztak K. Sirt1-Claudin-1 crosstalk regulates renal function. *Cell Metab* (2011) 14(2):298–309. doi:10.1016/j.cmet.2011.06.002.

64. Thomas MC, Tikellis C, Kathirzadis P, Burns WC, Cooper ME, Forbes JM. The role of advanced glycation in reduced organic cation transport associated with type 2 diabetes and nephropathy. *N Engl J Med* (2001) 345(12):861–9. doi:10.1056/NEJMoa011161.

65. Terada Y, Kowana J, Kobayashi T, Okado T, Suzuki N, Yoshimoto T, et al. Aldosterone-stimulated SGK1 activity mediates proinflammatory signaling in the mesangium. *J Am Soc Nephrol* (2008) 19(2):298–309. doi:10.1681/ASN.2007050531.

66. Panchapakesan U, Pollock C, Saad S. Renal epithelial growth factor receptor: its role in sodium and water homeostasis in diabetic nephropathy. *Clin Exp Pharmacol Physiol* (2011) 38(11):948–54. doi:10.1111/j.1440-1681.2010.05742.x.

67. Hills CE, Bland R, Bennett J, Ronco PM, Squires PE. High glucose upregulates ENaC and SGK1 expression in HCD-cells. *Cell Physiol Biochem* (2006) 18(6):337–46. doi:10.1159/000097611.

68. Chen KH, Hung CC, Hsu HH, Jing YH, Yang CW, Chen JK. Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-beta/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats. *Chem Biol Interact* (2011) 190(1):45–53. doi:10.1016/j.cbi.2010.11.033.

69. Lee MJ, Feliers D, Satyanarayan K, Mairappon MM, Li M, Barnes JL, et al. Resveratrol ameliorates high glucose induced protein synthesis in glomerular epithelial cells. *Cell Signal* (2010) 22(1):65–70. doi:10.1016/j.cellsig.2009.09.011.

70. Takao K, Singh K, Kabra D, Sharma V, Gaiwad A. Change in histone H3 phosphorylation. MAP kinase p38, PI3 K and p53 expression by resveratrol in preventing streptozotocin induced type 1 diabetic nephropathy. *Free Radic Res* (2008) 42(4):397–404. doi:10.1080/10715760801998646.

71. Wu L, Zhang Y, Ma X, Zhang N, Qin G. The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. *Mol Biol Rep* (2012) 39(9):9085–93. doi:10.1007/s11033-012-1780-6.

72. Xu Y, Nie L, Yin YC, Tang JH, Zhou JX, Li DD, et al. Resveratrol protects against hyperglycemia-induced oxidative damage to mitochondria by activating SIRT1 in rat mesangial cells. *Toxicol Appl Pharmacol* (2012) 259(3):395–401. doi:10.1016/j.taap.2011.09.028.

73. Maeda S, Koya D, Araki S, Babazono T, Umezono T, Toyoda M, et al. Association between single nucleotide polymorphisms within genes encoding sirtuin...
families and diabetic nephropathy in Japanese subjects with type 2 diabetes. Clin Exp Nephrol (2011) 15(3):381–90. doi:10.1007/s10157-011-0418-0

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 29 August 2014; accepted: 25 September 2014; published online: 09 October 2014.

Citation: Yacoub R, Lee K and He JC (2014) The role of SIRT1 in diabetic kidney disease. Front. Endocrinol. 5:166. doi: 10.3389/fendo.2014.00166

This article was submitted to Cellular Endocrinology, a section of the journal Frontiers in Endocrinology.

Copyright © 2014 Yacoub, Lee and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.